主页
市场
图表与思路
Algo
新闻
商店
经纪商
下载
经济日历
交易信号
网页端
热图
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GPCR
#1508
Structure Therapeutics Inc - American Depositary Shares
39.3
4
USD
-2.07%
版块:
医疗保健
基础:
USD
利润货币:
USD
日范围
年范围
日变化
-2.07%
每月变动
-4.79%
6个月变化
+11.57%
年变化
+47.12%
前一天收盘价
40.1
7
Open
39.3
4
最低价
39.3
4
High
39.3
4
交易量
48
市场
US Stock Market
医疗保健
GPCR
展开完整图表
完整图表
Financials
概览
声明
统计
每季度
年度
Market Capitalization
2.8 B
Employee
220
Founded
2016
CEO
N/A
Website
www.structuretx.com
Headquarter
Cayman Islands
FIGI
BBG01CBVHLW1
Industry
生物技术
总收入
净利润
每股基本收益(基本 EPS)
总债务
自由现金流
现金及现金等价物
新闻
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
NVO Rallies 21% in a Month: How Should Investors Play the Stock?
LLY Stock Pops 16% After Beat-and-Raise Q1: Buy, Hold or Take Profits?
Lilly's Oral GLP-1 Pill Foundayo Starts Strong in Oral Obesity Market
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Kailera Stock (KLRA) Rockets 68% after IPO in Race for $150B Obesity Market - TipRanks.com
LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study